Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of JNJ-69095897 in Healthy Participants
NCT04920578Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-69095897 in anxiety disorder and post-traumatic stress disorder (PTSD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Vital Sign Abnormalities, Number of Participants with Clinical Laboratory Abnormalities and 6 more. Started Jun 2021; status: terminated.
02
Drugs
JNJ-69095897
03
Conditions
anxiety disorderpost-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT04920578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04920578.